Publications, Presentations & Articles

Publications by Meg Boulware

  • “Interview”: Randi Karpinia, Meg Boulware and the AIPLA Women in IP Law Committee, Managing Intellectual Property, The Global IP Resource, December 2016.
  • Trademark Trial and Appeal Board Mock Trial Participant State Bar of Texas Advanced Intellectual Property Law February 18, 2016.
  • “Hurricane Alice and Patent Prosecution” State Bar of Texas, Advanced Intellectual Property Law, March 19, 2015.
  • “Branding Strategies For New Companies”, State Bar of Texas, June 27, 2014 “For the New Company on the Block: How Cool Do You Want to Be?”, American Intellectual Property Law Association Mid-Winter Institute, January 2014.
  • “Strategic Use of Post Grant Proceedings Under the AIA”, State Bar of Texas, Advanced Intellectual Property Law February 2013.
  • “What to do about Twitter Social Media Sites Upsetting Clients”, USC Gould School of Law 2012 Institute for Corporate Counsel; December 2012; American Intellectual Property Law Association Spring Meeting, May 2012
  • “The Legal Aspects of Performing Copyrighted Music” BMI
  • “Recent Decisions Affecting Patent Law” Intellectual Property Owners Association Annual Meeting, Atlanta, Georgia, September 2010
  • “Emerging Protection for Non-Traditional Trademarks: Product Packaging and Design,”Aspatore Books Inside the Minds: Recent Trends in Trademark Protection – Leading Lawyers on Analyzing Recent Decisions and Adapting to Evolution in Trademark Law, October 2009.
  • “Challenging Licensed Intellectual Property Rights Under U.S. and European Laws – The U.S. Supreme Court Abandons the Principle of Licensee Estoppel,” International Review of Intellectual Property and Competition Law, Max Planck Institute for Intellectual Property, Competition and Tax Law, Vol. 38, pages 757-880, November, 2007
  • “Partnering With Big Pharma…Tips From The Inside,” BioHouston, Inc., Houston, Texas, August 30, 2006
  • “A Tale of Two Roles: Functionality Analysis of Marks,” State Bar of Texas, 18th Annual Intellectual Property Law Course, Austin, Texas, March 2005.
  • “Patent Quality,” Intellectual Property Owner’s Association, Annual Meeting, Los Angeles, California, September 2002
  • “Patent Public Advisory Committee Report on Patent and Trademark Office,” Texas Technology Conference, The Woodlands, Texas, January 2001
  • “Privatization of the Internet and Intellectual Property Considerations,” International Association of Defense Counsel Midyear Meeting, Palm Springs, California, January 2001
  • “Non-Statutory Defenses, Inequitable Conduct and Rule 11,” Practicing Law Institute Patent Litigation 2000, New York, New York, October 2000
  • “E-Commerce and Privatization of the Internet,” International Paper Customer Counsel Council Meeting, Palm Harbor, Florida, March 15-17, 2000
  • “Inequitable Conduct, Laches and Other Nonstatutory Defenses,” Practicing Law Institute Patent Litigation 1999, New York, New York, November 1999
  • “Determining the Probability of Litigation Outcome: Risk Analysis and Other Case Management Techniques,” The 11th National Conference for Women Corporate Counsel, Washington, D.C., 1999
  • “Use of Affidavits and Data in Patent Prosecution,” ABA Section of Intellectual Property, Arlington, Virginia, 1997
  • “International Intellectual Property and Special Considerations,” State Bar of Texas Professional Development, Austin, Texas, March 1997
  • “An Overview of Intellectual Property Rights Abroad,” Hou. J. Int’l. L., Vol. 16, No. 3, Spring 1994
  • “Technology Transfer and Protection in Mexico – Then (1980s) and Now (1990s),” State Bar of Texas Professional Development Program, Intellectual Property Law 1992, Austin, Texas, February 1992
  • “Protecting Your Client’s Intellectual Properties Abroad,” State Bar of Texas Annual Meeting, Corpus Christi, Texas, 1992
  • “Opinions of Counsel in Patent Litigation,” Practicing Law Institute, New York, New York, 1990
  • “Foreign Patents,” ALI-ABA Securing and Enforcing Patent Rights, Washington, D.C., 1990
  • “Alternative Dispute Resolution,” 5th Annual Intellectual Property Law Institute, Sponsored by the Houston Intellectual Property Law Association, Houston, Texas, 1989
  • “Avoiding Inequitable Conduct in Chemical and Biotech Applications,” American Intellectual Property Law Association, Basic Chemical and Biotechnology Practice Seminar, San Francisco, California and Washington, D.C., 1988
  • “Issues of Fraud, Inequitable Conduct and Willful Infringement in Cases Before the Courts and the PTO,” Intellectual Property Symposia, Marco Island, Florida, 1988
  • “Issues of Fraud, Inequitable Conduct and Willful Infringement in Cases Before the Courts and the PTO,” American Bar Association, Arlington, Virginia, 1987
  • “Using Data and Affidavits in the PTO – Avoiding Inequitable Conduct”, Houston Intellectual Property Law Association and the State Bar of Texas, The Woodlands, Texas, 1986
  • “Avoiding Inequitable Conduct: Proper Use of Data and Affidavits and a Review of Fraud Under the CAFC,” American Intellectual Property Law Association, Washington, D.C., 1986
  • “Use of Affidavits and Duty of Candor,” American Intellectual Property Law Association, Chemical Practice Basics Seminar, Chicago, Illinois, 1986
  • “Candor in Prosecution,” Monograph, Editor and Contributor, American Intellectual Property Law Association, 1985

Publications by Tamsen Valoir

  • Valoir, Tamsen, “Who Will Finance Drug Development If Natural Products Are No Longer Patentable?”, Intellectual Property & Technology Law Journal, Vol. 28, No. 6, 3-9 (2016)
  • Breast Cancer, Politics, and Patents, AIPLA Quarterly Journal, Vol. 44, No. 1; Page 63, Winter 2016.
  • Valoir, Tamsen, “Discoveries Not Patentable: Isn’t That Unconstitutional?”, Intellectual Property & Technology Law Journal, 27(7); 16-18 (2015)
  • Valoir, Tamsen and Ellison, Sparkle T., “The Duty of Candor Under the AIA.” 29th Annual Intellectual Property Law Institute, Sponsored by the Houston Intellectual Property Law Association, Galveston, Texas, 2013.
  • Mayo v. Prometheus: Natural Law or Mental Step?
  • Valoir T., PhD & Ghosh S., PhD, FDA Preemption Of Drug And Device Labeling: Who Should Decide What Goes On A Drug Label? Health Matrix 21: 555-598 (2012).
  • Valoir, T., US Patent Basics, 7th Ed. (2012).
  • Valoir, T., Mining an Intellectual Property Portfolio: Ten Steps to Increasing Revenue, Intellectual Property Today, 2-3 (2011).
  • Valoir, T., Paradiso, Linda J., Patent Strategy for Medical Products, Intellectual Property & Technology Law Journal, Vol. 23, No. 9, 8-13 (2011).
  • Valoir, T., Ramey, W., Bayh-Dole and the Statement of Government Support, Intellectual Property & Technology Law Journal, Vol. 23, No. 2, 9-14 (2011).
  • Valoir, T. PhD and Nijhof, M.G., Tax-Speak for Intellectual Property Counsel, Intellectual Property Today, at 30-34 (2010).
  • Todd Brandt, PhD, Sergio Legorreta-Gonzalez, Ling Wong and Tamsen Valoir, PhD, IP due diligence in the NAFTA free trade zone, in PLC Cross-border IP in Business Transactions Handbook 2009/10 (2009), available online at http://uk.practicallaw.com/
  • Valoir T., Dai, M., “M&A: Effective Global Intellectual Property Due Diligence,” Intellectual Property & Technology Law Journal 20(4): 1-8 (April 2008).
  • Valoir, T., Ramey, W., “The Exponential Burden of McKesson,” IP Today (April 2008).
  • Valoir, T., “Ten Tips for Navigating from the Laboratory to the Market Place,” online publication at Resources-for-Entrepreneurs at Gaebler.com (2008).
  • Valoir T. Jones J. “ScholAthelete’s Survival Guide: Essential Study Skills for the Scholar Athlete” (2008) by Booklocker.
  • Valoir T., Dai, M., Effective Global Intellectual Property Due Diligence, in Mergers & Acquisitions and Intellectual Property, p. 7-11 (2008), published by BNA International Inc.Valoir, T., “Doing Business with the US Government,”IAM, pg. 9 (March, 2007).
  • Valoir, T., “Intellectual Property: Overlapping Types,” Wiglaf Journal (2007).
  • Valoir, T., Abdon, R., & Wong, L., “Calculating Patent Term: A Tricky Business,” Intellectual Property & Technology Law Journal 19(4):15-19 (2007).
  • Valoir T., Hricik D., “Patents and Trademarks: The Duty of Good Faith,” J. Patent & Trademark Office Society89(4): 287-300 (2007).
  • Valoir, T., “Ten Due Diligence Steps for IP Buyers,” Managing IP, p. 39-42 (2007).
  • Valoir, T., “Exploring the Intersection Between Tax and Intellectual Property,” The Tax Magazine, p. 19-22 (2007).
  • Valoir T., Hricik D., “Patents Compared to Trademarks: The Duty of Candor/The Avoidance of Fraud,” The Trademark Reporter 97(6): 1317-1331 (2007). Valoir, T., “Six Ways to Preserve Market Exclusivity,” Intellectual Property Today, (July, 2006).
  • Valoir, T., “Patent Term Extensions and Other means of Preserving Market Exclusivity,” Intellectual Property Today, at 30-32 (2006).
  • Valoir, T., “Intellectual Property Due Diligence—A Cautionary Tale,” BNA International: Intellectual Property & Technology Programme (2006).
  • O’Connor D.J. & Valoir T., “The Supreme Court Tilts Toward Drug Developers: Drug Discovery After Merck v. Integra” Chicago-Kent Journal of Intellectual Property Law 5(2): 124-140 (2006).
  • Valoir, T., “Law School Survival Guide” (2005) by Booklocker.
  • Valoir, T., “Look Before You Leap: Investing in a Freedom-to-Operate Review,” Executive Legal Adviser, p. 20, Jan. 2005.
  • Valoir, T., “Restriction Versus Election of Species,” Intellectual Property Today, p. 30 (April 2005).
  • “Practical Patent Prosecution Training for New Lawyers: How to Manual” (AIPLA, Valoir & Albin, Eds. 2005).
  • Valoir, T., “IP Due Diligence: Top Ten Tasks” The M&A Lawyer, p. 20 (June 2005).
  • Valoir, T. “Deposition Transcripts: Subject to Copyright Protection?” Intellectual Property & Technology Law Journal, 17(7): 1-5 (2005).
  • Valoir, T., “Drug Discovery After v. Merck” Intellectual Property & Technology Law Journal, 17(10): 1-4 (2005).
  • Valoir T., Intellectual Property & Technology Law Journal 17(11): 7-10 (2005).
  • Valoir T., “For the Taking: The Supreme Court extended the power of eminent domain. Now states want to issue compulsory licenses under the same principle to control drug prices,” Pharmaceutical Executive, p. 44 (Nov. 2005).
  • Valoir, T., “Generic Treatment Claims: One District Court Decides They are Invalid,” John Marshall Law School Center for Intellectual Property Law News Source, 4(3): 15-17 (2003).
  • Valoir, T., “Generic Treatment Claims: Do They Hold Water?,” Pharmaceutical Executive, p. 60 (April 2003).
  • Hunziker, R. & Valoir, T., “Government Venture Capitalism Often Overlooked In Biotech Area,” Houston Business Journal, July 26, 2002.
  • Valoir, T., “The Duty Of Candor In Patent Applications: What It Is And How To Comply With It,” Intellectual Property & Technology L. J., 14(3): 9-13 (2002).
  • Valoir, T., “The Bayh-Dole Act: Eight Points That Every Technology Company Should Know,” Intellectual Property Today, at 36 -37 (Nov. 2001).
  • Valoir, T., “Government Funded Inventions; The Bayh-Dole Act and the Hopkins v. CellPro March-In Rights Controversy,” Texas Intellectual Property Law Journal 82(2): 211 (2000).
  • Boulware, M. A. & Valoir T., “Inequitable Conduct: A Nonstatutory Defense,” in Patent Litigation 1999, at 1155 (Practicing Law Institute, 1999).
  • Valoir, T., “The Obviousness of Cloning,” Intellectual Prop. Law J., 9(3): 349-375 (1995).
  • Brewster, J., Valoir, T., Dwyer, N., Martin E., Gustin, M., “An osmo-sensitive signal transduction pathway in yeast growth and osmolarity regulation by two protein kinases,” Science, 259: 1760-63 (1993).
  • Valoir, T., Tucker, M.A., Belikoff, E.J., Camp, L.A., and Beckingham, K., “A second maternally expressed Drosophila gene encodes a “DEAD box” protein,” P.N.A.S., 88: 2113-2117 (1991).
  • Rubacha, A., Tucker, M.A., Valoir, T., Belikoff, E.J., and Beckingham, K., “Oogenesis specific genes of Calliphora erythrocephala,” Develop. Biol., 129: 449-463 (1988).
  • Valoir, T., Belikoff, E., Rubacha, A., Tucker, M., and Beckingham, K., “Studies of an oogenesis-specific, germline expressed gene which is conserved in Calliphora erythrocephala and Drosophila melanogaster,” (Abstract for Lost Pines Molecular Biology Conference), Oct. 1987.
  • Tucker, M.A., Valoir, T., Belikoff, E., and Beckingham, K., “Characterization of germ-line transcribed oogenesis-specific genes,” (Abstract for 28th Annual National Drosophila Research Conference), May 1987.
  • Tucker, M.A., Belikoff, E.J., Rubacha, A., Valoir, T., and Beckingham, K., “Isolation of oogenesis-specific genes from Dipteran Calliphora erythrocephala,” (Abstract for Lost Pines Molecular Biology Conference), Oct. 1986.
  • Carter, R., Schroeter, J., and Valoir, T., “Economic measures for the U.S. penal system,” J.I.R., 31: 2-3 (1985).
  • Trudel, M., Van Genechten [Valoir], T., and Meuth, M., “Biochemical characterization of the hamster Thy-mutator gene and its revertants,” J. Biol Chem., 259: 2355-2359 (1984).

© Copyright 2023 | All Rights Reserved | Powered by PERPAX IT Solutions